Editorial: Altered metabolic traits in gastro-intestinal tract cancers, volume II

Objective:

To highlight the critical role of altered metabolic traits and tumor microenvironment in the prognosis and management of gastrointestinal tract cancers.

Key Findings:

• Elevated pre-treatment SII predicts poor survival in CRC, indicating a need for early intervention.
• TyG index correlates with increased risk of CRC and serves as a prognostic marker for pancreatic cancer, suggesting its use in risk stratification.
• Remnant cholesterol is associated with tumor grade in pancreatic neuroendocrine neoplasms, indicating its potential as a biomarker.
• Dysregulated MYC and TGF-β signaling contribute to therapy resistance in neuroendocrine tumors, highlighting targets for future therapies.

Interpretation:

The findings underscore the importance of metabolic markers and the tumor microenvironment in understanding cancer progression and improving diagnostic and therapeutic strategies, paving the way for future research.

Limitations:

• Predominantly retrospective study designs limit the reliability of findings and introduce potential biases.
• Variable cut-off values hinder standardization and translational applicability, necessitating uniform criteria.

Conclusion:

A systemic approach integrating metabolic and inflammatory indices may enhance the management and prognosis of gastrointestinal cancers, necessitating further prospective studies to validate these findings.